Tuesday 16 May 2023
08:00
08:00 - 08:45 Sponsored breakfast meeting I
Please view more detailed information about this program item under the tab sponsored sessions.
08:00 - 08:45 [CLOSED meeting] SIOPEN Board meeting
08:00 - 08:45 Educational Session 1
08:00
Diagnostics and Staging in NB - assays, risk, current standard and new perspectives
Susan Cohn, United States
08:20
Neuroblastoma phenotypic states integrate multiple mutational and epigenetic changes
Frank Westermann, Germany
09:00 -10:00 Plenary session 3: Clinical trials and relapse treatment
Moderators: Yael Mossé, United States & Angelika Eggert, Germany
09:00
PS3.1 History of HR-NBL treatment
Julie Park, United States
09:15
PS3.2 SIOPEN-HR2: essentials of current high risk treatment protocol
Dominique Valteau, France
09:30
PS3.3 COG-ANBL1531: essentials of current high risk treatment protocol
Steve Dubois, United States
09:45
PS3.4 Relapse trials
Lucas Moreno, Spain
10:00
10:00 - 10:10 In Memoriam Audrey Evans
John Maris & Garrett Brodeur, United States
10:10
10:10 - 10:40 Coffee break
10:40 - 11:30 Parallel session 5: Metabolomics
Moderators: Murray Norris & Marie Arsenian Henriksson
10:40
O5.1 Maternal high fat diet accelerates neuroblastoma tumorigenesis
Belamy Cheung, Australia
10:52
O5.2 Ferroptosis, a novel liability of high-risk neuroblastoma
Karolina Garbowicz, Germany
11:04
O5.3 Reprogramming the neuroblastoma epigenome with mitochondrial uncoupler to promote differentiation therapy
Jiangbin Ye, United States
11:16
O5.4 Optimising polyamine inhibition therapy combined with standard-of-care chemotherapy and anti-GD2 immunotherapy through preclinical modelling in Th-MYCN mice
Jayne Murray, Australia
10:40 - 11:30 Parallel session 6: Clinical cohort studies
Moderators: Rochelle Bagatell, United States & Pat Reynolds, United States
10:40
O6.1 Growth retardation in long-term high-risk neuroblastoma survivors treated with high-dose chemotherapy
Dominique Valteau-Couanet, France
10:52
O6.2 High Risk Neuroblastoma (HR-NB) with MNA and age <18months: Results from the HR-NBL1/SIOPEN trial
Ruth Ladenstein, Austria
11:04
O6.3 Improved outcome for patients with alternative lengthening of telomeres (ALT) neuroblastoma randomized to tandem myeloablative therapy on COG ANBL0532
Patrick Reynolds, United States
11:16
O6.4 A Multicenter Cooperative Group Study of Survivors of High-Risk Neuroblastoma: The Late Effects after High-Risk Neuroblastoma (LEAHRN) Study (COG ALTE15N2)
Lisa Diller, United States
10:40 - 11:30 Parallel session 7: Genetic defects and dependencies in neuroblastoma
Moderators: Tao Liu, Australia & Michael Hogarty, United States
10:40
O7.1 SOX11 is a mediator of core regulatory circuit robustness: upregulation of SWI/SNF components and recruitment of transcriptional enhancer NONO
Amber Louwagie, Belgium
10:52
O7.2 Interplay between LDB1 and core transcription factors instructs enhancer-promoter interactions and determines cell-fate in neuroblastoma
Zhihui Liu, United States
11:04
Regulatory non-coding somatic mutations as drivers of neuroblastoma
Annalaura Montella, Italy
11:16
O7.4 Parallel sequencing of extrachromosomal circular DNA and mRNA in single neuroblastoma cells
Maria Del Rocio Chamorro Gonzalez, Germany
11:30
11:30 - 13:30 [CLOSED MEETING] Parents Organizations
11:30 -11:45 Rapid Fire session 1B
Moderator: Bram de Wilde, Belgium
11:31
P127 Exploring the role of MYCN in the mitochondria to discover MYCN-Amplified tumour vulnerabilities
Soraya Epp, Ireland
11:32
P126 CDK12 as a target for combinatorial drugging of high-risk neuroblastoma
Joshua Robert Goulding, Belgium
11:33
P131 Joint inhibition of oncogenic and epigenetic targets PPM1D and KDM6B synergistically suppresses neuroblastoma growth
Diana Treis, Sweden
11:34
P125 Drug repurposing for high-risk neuroblastoma
Katarzyna Radke, Sweden
11:35
P076 Atypical neuroblastoma: screening of urinary catecholamine excretion and mIBG avidity at diagnosis, a retrospective study
Anna Borovkov, France
11:36
P077 Cause and consequence of intra- and inter-tumor heterogeneity in zebrafish models of neuroblastoma
Nora Fresmann, Germany
11:37
P296 Long-term Follow-up of the Children’s Oncology Group (COG) Intermediate-risk Phase III ANBL0531 Study Using Response- and Biology-Based Therapy
Erin Barr, United States
11:38
P297 Predictors of Differential Outcomes According to Response to Induction Chemotherapy in High-Risk Neuroblastoma
Elizabeth Sokol, United States
11:39
P271 Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma: An International Neuroblastoma Risk Group Project
Mohansrinivas Chennakesavalu, United States
11:40
P298 Response-Adapted Consolidation Therapy Strategy for Patients With Metastatic High-Risk Neuroblastoma: Results From the SMC NB-2014 Study
Eun Seop Seo, South Korea
11:45
11:45 - 12:45 Lunch + Poster Session group B
Poster viewing: P001-P191 - Poster Session Group B: P111 until P191
12:00
12:00 - 13:00 [CLOSED MEETING] ANRA Advisory Board Meeting
13:45 - 14:30 Keynote Lecture 2
Moderator: Max van Noesel, the Netherlands
13:45
Drug development in Pediatric Oncology
Michel Zwaan, the Netherlands
14:30 - 15:30 Plenary session 4: Precision therapy
Moderators: Michelle Haber, Australia & Louis Chesler, UK
14:30
PS4.1 Phase 2 trial of the Wee1 inhibitor Adavosertib and Irinotecan in Neuroblastoma
Kristina Cole, United States
14:45
PS4.2 Mutated fibroblast growth factor receptor 1 is a strong oncogenic driver and a therapeutic target in neuroblastoma
Lisa Werr, Germany
15:00
PS4.3 Combined targeting of metabolic dependencies of proline translation in neuroblastoma
Raphael Johannes Morscher, Switzerland
15:15
PS4.4 Low GD2 expression as a mechanism of resistance to chemoimmunotherapy with dinutuximab
Michelle Keyel, United States
15:30
15:30 - 16:00 Coffee break
16:00 - 16:50 Parallel session 8: Precision therapy: Novel targets
Moderators: Rani George, United States & Anton Henssen, Germany
16:00
O8.1 Drug sensitivity profiling of 3D neuroblastoma cultures in the pediatric precision oncology program INFORM
Ina Oehme, Germany
16:12
O8.2 Interactive online repository demonstrating drug sensitivity associated with genomic and transcriptomic profiles of patient-derived neuroblastoma organoids and classical cell lines
Karin Langenberg, the Netherlands
16:24
O8.3 Drugging the ATR-CHK1-RRM2 replicative stress signalling axis in neuroblastoma: exploring deeper mechanistic insights and novel drugging options
Iris Nelen, Belgium
16:36
O8.4 Nanoarchitectonics of the M13 phage provides a potent and specific anti-GD2 vector platform for Neuroblastoma Therapy
Suleman Khan Zadran, Italy
16:00 - 16:50 Parallel session 9: Plasticity in neuroblastoma and normal development
Moderators: Adam Durbin, United States & Isabelle Janoueix, France
16:00
O9.1 Single-nuclei transcriptomes from human adrenal gland reveals distinct cellular identities of low and high-risk neuroblastoma tumors
Oscar Bedoya, Sweden
16:12
O9.2 Trunk neural crest enriched MOXD1 suppresses tumor growth in neuroblastoma
Elina Fredlund, Sweden
16:24
O9.3 A harmonized single-cell transcriptomic atlas of human neuroblastoma
Noah Bonine, Belgium
16:36
O9.4 Single-cell profiling of the neuroblastoma heterogeneity at the bone marrow metastatic niche
Magdalena Rados, Osterreich
16:00 - 16:50 Parallel session 10: Tumor-micro environment interactions
Moderators: Yves Declerck, United States & Sabine Taschner-Mandl, Austria
16:00
O10.1 Single-cell transcriptomics and epigenomics unravel the role of monocytes at the bone marrow metastatic niche in neuroblastoma
Irfete Fetahu, Austria
16:12
O10.2 Cancer-associated fibroblasts drive mesenchymal transition and therapeutic resistance via TGFb/NFkB signaling in neuroblastoma
Kevin Louault, United States
16:24
O10.3 Changes in the bone marrow microenvironment upon neuroblastoma metastasis
Ilse Timmerman, the Netherlands
16:36
O10.4 Macrophage infiltration promotes regrowth in MYCN amplified neuroblastoma after chemotherapy
Catharina Hagerling, Sweden
16:50
Poster session group B
Posters with reference P111 until P191
17:30
17:30 - 19:00 Young Investigator Reception
Dinner on your own